C- to CS-Mount Adapter - c cs mount adapter

 2024-09-15 17:07:43

Anti reflective coatingiPad

“We are elated that Stanford Medicine is the first healthcare provider to deliver SCINTIX treatment, marking the first delivery of autonomous radiotherapy,” said Sam Mazin, Ph.D., founder and CTO of RefleXion. “We have been working toward this milestone for over a decade, and on behalf of everyone at RefleXion, I want to thank our early adopter clinical sites, numerous advisors, and our investors for working alongside us to develop and bring to market this new option for patients with all stages of solid tumors.”

“This first SCINTIX treatment is a watershed moment for physicians and patients alike because finally, we have a technology with the potential to meet the challenges of treating metastatic disease head on,” said Todd Powell, president and CEO of RefleXion. “Clinical literature and emerging practice guidelines are beginning to incorporate the importance of treating all visible disease in certain cancers. SCINTIX was conceived with that end in mind, and to work in combination with drug therapies to improve outcomes, especially for patients with advanced-stage cancers.”

Anti Reflective coatingPhysics

Over the next several weeks, multiple renowned cancer centers in the United States, including City of Hope Comprehensive Cancer Center in Southern California, and sites in Pennsylvania and Texas will begin offering SCINTIX therapy. By the end of 2023, SCINTIX therapy will also be available in New Jersey, Connecticut and Oregon.

EKSMA Optics uses cookies to give you the best shopping experience. If you continue to use our services, we will assume that you agree to the use of such cookies.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Antireflectioncoatingformula

This first SCINTIX treatment is a watershed moment for physicians and patients alike because finally, we have a technology with the potential to meet the challenges of treating metastatic disease head on.

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Anti reflective coatingmaterial

Anti reflective coatingreddit

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

High reflectivity (HR) coatings for laser lines, broadband HR and partial reflecting (PR) coatings, laser harmonic separators, dichroic coatings and coatings for polarizing optics. Also, we deposit anti-reflection (AR), dual band and triple band AR for laser lines, broadband (BBAR) and metallic coatings. We use electron evaporation (e-beam), ion assistance deposition (IAD), thermal evaporation and advanced ion beam sputtered (IBS) technologies for deposition of coatings on optical and crystal elements.

Anti reflective coatingsunglasses

RefleXion is a privately held therapeutic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel treatment modality that uses a single radiotracer injection to transform cancer cells into real-time biological beacons to control external-beam radiotherapy delivery to multiple tumors. Granted Breakthrough Device designation for lung tumors and De Novo marketing authorization by the FDA, SCINTIX therapy is indicated for use in lung and bone tumors. These tumors may arise from primary lung and bone cancers or result from metastases to the lungs or bone from other primary cancers. The RefleXion X1 is also cleared for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and intensity modulated radiotherapy (IMRT) for solid tumors located anywhere in the body. RefleXion’s vision is to extend the established safety, efficacy and cost-effectiveness of external-beam radiotherapy to patients with solid tumor malignancies of any stage.

The FDA cleared SCINTIX biology-guided radiotherapy to treat patients with lung and bone tumors. These tumors may arise from primary cancers or from metastatic lesions spread from other cancers in the body. Prior to this, SCINTIX therapy was also designated as a Breakthrough Device for treating lung tumors due to its potential to precisely manage tumor motion.

HAYWARD, Calif., Aug. 23, 2023 – RefleXion Medical, a therapeutic oncology company, today announced that the first patient has completed treatment with SCINTIX™ biology-guided radiotherapy on the RefleXion® X1 machine at the Stanford Medicine Cancer Center. SCINTIX therapy is a cutting-edge radiopharmaceutical-directed treatment applicable for early and late-stage cancers that uses the individual biology of each tumor to drive its own treatment.

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Overcoming the hurdles of targeting and motion management, especially for multiple tumors, is the main challenge preventing external-beam radiotherapy from efficiently treating metastatic cancer. SCINTIX therapy uses emissions from cancer cells created by injecting the patient with a radiopharmaceutical to deliver a radiation dose that continuously and autonomously targets the cancer itself. Moreover, this fundamental capability simultaneously lights up all indicated cancer targets in the body during treatment. The X1 with SCINTIX is the only dual-treatment modality radiotherapy platform in the world that can treat patients with indicated solid tumors of any stage.

Anti reflective coatingspray